Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | = 20.33 | Analgesic activity in Swiss Albino mouse assessed as number of acetic acid-induced writhing at 100 mg/kg, po after 1 hr relative to control | ChEMBL. | 17964781 |
Inhibition (functional) | = 26 % | Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, after 2 hrs | ChEMBL. | 17964781 |
Inhibition (functional) | = 30 % | Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, after 24 hrs | ChEMBL. | 17964781 |
Inhibition (functional) | = 32.81 % | Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, after 4 hrs | ChEMBL. | 17964781 |
Inhibition (functional) | = 34.38 % | Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, after 1 hr | ChEMBL. | 17964781 |
Inhibition (functional) | = 34.78 % | Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, after 3 hrs | ChEMBL. | 17964781 |
Inhibition (functional) | = 37.04 % | Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, after 6 hrs | ChEMBL. | 17964781 |
Inhibition (functional) | = 41.36 % | Analgesic activity in Swiss Albino mouse assessed as inhibition of acetic acid-induced writhing responses at 100 mg/kg, po after 1 hr | ChEMBL. | 17964781 |
Inhibition (functional) | = 41.36 % | Analgesic activity in Swiss Albino mouse assessed as inhibition of acetic acid-induced writhing responses at 100 mg/kg, po after 1 hr | ChEMBL. | 17964781 |
UI (ADMET) | = 0 | Toxicity in 24 hrs fasted Wistar rat assessed as ulcer index at 100 mg/kg, po after 6 hrs | ChEMBL. | 17964781 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.